Twist Bioscience Reports First Quarter Fiscal 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Twist Bioscience Corporation (TWST) Misses Q1 EPS by 86c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Below Consensus
February 6, 2020 4:45 PM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q1 EPS of ($1.69), $0.86 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $17.16 million versus the consensus estimate of $16.07 million.
FISCAL 2020 FIRST QUARTER FINANCIAL RESULTS
Orders: Total orders received for the first quarter of fiscal 2020 were $24.8 million, compared to $15.2 million for the same period of fiscal 2019.Revenue: Total revenues were $17.2 million for the first quarter of fiscal 2020 compared to $11.5 million for the same period of fiscal 2019.Cost of Revenues: Cost of revenues for the first quarter of fiscal 2020 was $13.8 million... More